Insmed Inc Drug Patent Portfolio

Insmed Inc owns 1 orange book drug protected by 13 US patents Given below is the list of Insmed Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10251900 Methods for treating pulmonary non-tuberculous mycobacterial infections 15 May, 2035
Active
US10751355 Methods for treating pulmonary non-tuberculous mycobacterial infections 15 May, 2035
Active
US11446318 Methods for treating pulmonary non-tuberculous mycobacterial infections 15 May, 2035
Active
US12016873 Methods for treating pulmonary non-tuberculous mycobacterial infections 15 May, 2035
Active
US9895385 Methods for treating pulmonary non-tuberculous mycobacterial infections 15 May, 2035
Active
US9566234 Systems for treating pulmonary infections 18 Jan, 2034
Active
US8226975 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof 15 Aug, 2028
Active
US8632804 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof 05 Dec, 2026
Active
US8642075 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof 05 Dec, 2026
Active
US8679532 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof 05 Dec, 2026
Active
US7718189 Sustained release of antiinfectives 06 Jun, 2025
Active
US8802137 Sustained release of antiinfectives 08 Apr, 2024 Expired
US9827317 Sustained release of antiinfectives 08 Apr, 2024 Expired


Given below is the list of recent legal activities going on the following drug patents of Insmed Inc.

Activity Date Patent Number
Patent litigations
Notice of Final Determination- Ineligible 07 Feb, 2024 US8226975
Payment of Maintenance Fee, 4th Year, Large Entity 24 Jan, 2024 US10751355
Payment of Maintenance Fee, 12th Year, Large Entity 19 Dec, 2023 US8226975
Post Issue Communication - Certificate of Correction 12 Oct, 2022 US9566234
Patent Issue Date Used in PTA Calculation 20 Sep, 2022 US11446318
Recordation of Patent Grant Mailed 20 Sep, 2022 US11446318
Payment of Maintenance Fee, 4th Year, Large Entity 20 Sep, 2022 US10251900
Email Notification 01 Sep, 2022 US11446318
Issue Notification Mailed 31 Aug, 2022 US11446318
Application Is Considered Ready for Issue 23 Aug, 2022 US11446318
Dispatch to FDC 23 Aug, 2022 US11446318
Printer Rush- No mailing 19 Aug, 2022 US11446318
Information Disclosure Statement considered 19 Aug, 2022 US11446318
Pubs Case Remand to TC 08 Aug, 2022 US11446318
Information Disclosure Statement (IDS) Filed 05 Aug, 2022 US11446318


Insmed Inc Drug Patents' Oppositions Filed in EPO

Insmed Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jun 04, 2014, by Generics [Uk] Limited. This opposition was filed on patent number EP06787716A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP11159754A Feb, 2016 Generics [UK] Limited Revoked
EP06787716A Jun, 2014 Generics [UK] Limited Patent maintained as amended


Insmed Inc's Family Patents

Insmed Inc drugs have patent protection in a total of 29 countries. It's US patent count contributes only to 31.2% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Insmed Inc Drug List

Given below is the complete list of Insmed Inc's drugs and the patents protecting them.


1. Arikayce Kit

Arikayce Kit is protected by 13 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10251900 Methods for treating pulmonary non-tuberculous mycobacterial infections 15 May, 2035
(10 years from now)
Active
US10751355 Methods for treating pulmonary non-tuberculous mycobacterial infections 15 May, 2035
(10 years from now)
Active
US11446318 Methods for treating pulmonary non-tuberculous mycobacterial infections 15 May, 2035
(10 years from now)
Active
US12016873 Methods for treating pulmonary non-tuberculous mycobacterial infections 15 May, 2035
(10 years from now)
Active
US9895385 Methods for treating pulmonary non-tuberculous mycobacterial infections 15 May, 2035
(10 years from now)
Active
US9566234 Systems for treating pulmonary infections 18 Jan, 2034
(9 years from now)
Active
US8226975 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof 15 Aug, 2028
(3 years from now)
Active
US8632804 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof 05 Dec, 2026
(2 years from now)
Active
US8642075 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof 05 Dec, 2026
(2 years from now)
Active
US8679532 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof 05 Dec, 2026
(2 years from now)
Active
US7718189 Sustained release of antiinfectives 06 Jun, 2025
(7 months from now)
Active
US8802137 Sustained release of antiinfectives 08 Apr, 2024
(6 months ago)
Expired
US9827317 Sustained release of antiinfectives 08 Apr, 2024
(6 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Arikayce Kit's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Insmed Inc News

Insmed's Stock Soars 150% Following Analysts' Predictions of Next Big Success

31 May, 2024

Insmed's latest study outcomes enable progress towards seeking FDA approval for a previously untreated lung disease.

28 May, 2024

See More